fregime
TODAYSTOCKSARCHIVEABOUTGUIDE
Sign inFollow your stocks

Write what you believe about your stocks; every morning the cited record grades it: supported, challenged, or untouched. Never opinions.

Development · 26 Sep 2026

ALKEM, full dossier

Alkem Labs' revenue grew 8.2 percent CAGR over FY23-26 to ₹14,712 crore in FY26, while PAT recorded a CAGR of 32 percent to ₹2,351 crore, aided by an improvement in the EBITDA margin from 14 percent in FY23 to 20.4 percent in FY26.

1 publisher has reported this development. Each act of reporting is below, cited.

The record

Alkem Labs' revenue grew 8.2 percent CAGR over FY23-26 to ₹14,712 crore in FY26, while PAT recorded a CAGR of 32 percent to ₹2,351 crore, aided by an improvement in the EBITDA margin from 14 percent in FY23 to 20.4 percent in FY26.

thehindubusinessline.com26 Sep 2026

A single act of reporting so far, corroborating sources join this record as they publish.

Alkem Laboratories

₹5,220.00

▲ +1.09%

Close (EOD), as of 1 Oct 2026 · source

Alkem Laboratories: results, dividends, orders, the full cited record →

More on Alkem Laboratories

Alkem Laboratories Chief Financial Officer Nitin Agrawal resigned from his post on July 30 to pursue new professional opportunities.

26 Sep 2026 · 1 publisher

Alkem Laboratories shares fell in afternoon trade on Thursday after the company announced the resignation of its Chief Financial Officer and Key Managerial Personnel Nitin Agrawal.

25 Sep 2026 · 1 publisher

Dr Reddys Laboratories Ltd is quoting at Rs 1213, up 0.17% on the day as on 12:44 IST on the NSE.

24 Sep 2026 · 2 publishers

India's 10 largest pharmaceutical companies have maintained positive average volume growth through every month of 2026 so far, while smaller rivals have seen a more uneven performance.

20 Sep 2026 · 1 publisher

Alkem Laboratories has announced the launch of NeuCeno (cenobamate), an anti-seizure medication for the treatment of partial-onset seizures in adult patients.

17 Sep 2026 · 5 publishers

Every claim carries its citation

This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.

New here? The reader's guide explains every page, plate by plate.

fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.